Bristol-Myers (BMS) Divests its UPSA Consumer Health Business to Taisho

 Bristol-Myers (BMS) Divests its UPSA Consumer Health Business to Taisho

Bristol-Myers (BMS) Divests its UPSA Consumer Health Business to Taisho

Shots:
  • Taisho to acquire BMS’ UPSA Consumer Health Business for $1.6B, in all stock transaction
    with the put option. The transaction is expected to close in H1’19
  • The focus of the agreement is to allow BMS to emphasize on its portfolio offering treatments in serious diseases and strengthen Taisho’s OTC platform
  • UPSA develops and delivers medicines in multiple therapeutic areas like pain, cough & cold, gastrointestinal and sleep for patients in France, across EU and additional countries

Click here to read full press release/ article | Ref: Bristol Myers Squibb | Image:The Irish Time

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post